SCLXW Company Profile and Key Details

Q: Who are the executives of SCLXW?

Mr. Suketu D. Desai Ph.D.Chief Technical OfficerMr. Steven F. Lincoln J.D.Interim Gen. Counsel & Chief Compliance OfficerMr. Jaisim ShahPres, Chief Executive Officer & DirectorDr. Dmitri V. Lissin M.D.Senior Vice President & Chief Medical OfficerMr. Suresh K. KhemaniSenior Vice President & Chief Commercial OfficerDr. Henry H. Ji Ph.D.Executive ChairmanMs. Elizabeth Adkins Czerepak M.B.A.Executive Vice President, Chief Financial Officer, Chief Bus. Officer & Sec.

NASDAQ : SCLXW

Scilex

$0.14

-0.0004-0.29%

At Close 4:00 PM

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Scilex Holding Company (SCLXW) stock declined over -0.29%, trading at $0.14 on NASDAQ, down from the previous close of $0.14. The stock opened at $0.12, fluctuating between $0.12 and $0.14 in the recent session.

Stock Snapshot

0.14

Prev. Close

1.19M

Market Cap

0.1215

Day Low

N/A

P/E Ratio

N/A

EPS (TTM)

-0.21

Cash Flow per Share

0.12

Open

8.54M

Number of Shares

0.14

Day High

73.54%

Free Float in %

-1.73

Book Value

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Mar 24, 2026	0.14	0.14	0.14	0.14	5
Mar 23, 2026	0.12	0.14	0.10	0.14	2.14K
Mar 20, 2026	0.14	0.14	0.13	0.13	2.39K
Mar 19, 2026	0.13	0.17	0.13	0.16	8.46K
Mar 18, 2026	0.14	0.14	0.14	0.14	166
Mar 17, 2026	0.13	0.13	0.13	0.13	1.44K
Mar 16, 2026	0.13	0.13	0.13	0.13	5
Mar 10, 2026	0.14	0.14	0.14	0.14	540
Mar 09, 2026	0.12	0.14	0.12	0.13	1.12K
Mar 06, 2026	0.10	0.12	0.10	0.12	2.49K
Mar 03, 2026	0.10	0.15	0.10	0.15	2.25K
Mar 02, 2026	0.12	0.15	0.10	0.15	5.56K
Feb 27, 2026	0.14	0.18	0.14	0.15	5.47K
Feb 26, 2026	0.15	0.15	0.14	0.14	759
Feb 25, 2026	0.11	0.11	0.11	0.11	10
Feb 24, 2026	0.16	0.16	0.11	0.15	2.95K
Feb 23, 2026	0.12	0.16	0.12	0.16	695
Feb 20, 2026	0.17	0.17	0.11	0.16	2.26K
Feb 19, 2026	0.15	0.15	0.15	0.15	158
Feb 18, 2026	0.13	0.15	0.11	0.13	2.26K

Contact Details

Palo Alto, CA 94303

United States

https://www.scilexholding.com 650 516 4310

About Company

Scilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid therapies for patients with acute and chronic pain. The company's principal product includes ZTlido 1.8%, a prescription lidocaine topical product for the relief of neuropathic pain related with post-herpetic neuralgia, which is a form of post-shingles nerve pain. It also offers SP-102 or SEMDEXA, a viscous gel formulation of corticosteroid for epidural injections that is in a Phase 3 clinical trial to treat lumbosacral radicular pain; SP-103 for the treatment of low back pain, which is in Phase 2 clinical trails; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation for the treatment of fibromyalgia that is in Phase 1 clinical trials. The company is headquartered in Palo Alto, California. Scilex Holding Company is a subsidiary of Sorrento Therapeutics, Inc.

Stock Peers

AMGN

-1.34-0.38%

Amgen Inc.$348.43 BIIB

0.3+0.16%

Biogen Inc.$183.94 GILD

0.77+0.56%

Gilead Sciences, Inc.$138.11 HZNP

Horizon Therapeutics Public Limited Company$116.30 SNY

0.37+0.83%

Sanofi$45.14 GRFS

-0.09-1.17%

Grifols, S.A.$7.60 SCLX

-0.74-10.07%

Scilex Holding Company$6.61 MIRA

-0.075-6.67%

MIRA Pharmaceuticals, Inc.$1.05 CTOR

-0.0427-6.83%

Citius Oncology, Inc.$0.58

Company Overview

The stock is currently mid-range between its 52-week high and low $0.10 and $0.17. With a market capitalization of about $1.19 million, Scilex Holding Company is classified as a micro-cap and shows higher-than-market volatility (beta ~1.37). Key stats such as the average daily volume over the past year has been around 18.66 thousand shares, volume is running light vs its 52-week average. Headquartered in Palo Alto, CA, Scilex Holding Company operates in the Healthcare sector and the Drug Manufacturers - General industry. Led by CEO Henry H. Ji, the company employs approximately 115 people and listed since March 05, 2021. Scilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid therapies for patients with acute and chronic pain.

Technical Performance

Average 10-day trading volume of 2.09 thousand shares is below the 3-month average of 5.04 thousand, indicating normal recent market interest.

Valuation Metrics

Scilex Holding Company trades at a P/E ratio of -0.21, slightly below the S&P 500 average, with a price-to-sales ratio of 1.43 and a price-to-book ratio of -0.44 indicating negative book value, which may reflect financial stress. The P/FCF stands at 2.42, also below market averages.

Dividend & Fair Value

Dividend and splits history remains an important factor for investors monitoring long-term returns.

Earnings & Analyst Outlook

Scilex Holding Company earnings surprise history is a mixed track record. The quarter that ended November 14, 2025, missed forecasts by 2616.96%. The prior quarter beat by 300.97%. Over the last six quarters, Apple has recorded several small beats. These include 300.97% in August 13, 2025.

Financial & Profitability Overview

Over the trailing twelve months, Scilex generated $46.74M in revenue, or $0.36 per share. Gross margin was 57.58%, operating margin -225.55%, and net profit margin -244.59%. Returns are negative, with ROA at -112.85% and ROE at 66.11%.
On valuation metrics, Scilex trades at a P/E of -0.21, P/S of 1.43 and P/B of -0.44. Liquidity is tight, with a current ratio of 0.05 and quick ratio of 0.04. Operationally, the company’s inventory turnover is 11.72 and cash conversion cycle is -1800.51 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is -0.38, supported by a cash flow-to-debt ratio of 0.35.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Scilex posted revenue of $46.74M, down slightly from $38.03M in the prior quarter. Gross profit was $26.92M (margin 57.58%). Operating income was - $105.43M (margin -225.6%). Net income was- $114.33M (EPS - $0.88).
The company ended the quarter with $3.92M in cash and short-term investments, a total debt of $128.46M, and net debt of $124.54M. Total assets were $101.31M, with equity of - $172.94M. Financials further reflected weakness, with operating cash flow of - $20.71M, free cash flow of - $21.04M, and capital expenditures of - $330.00K.

Price Forecast & Outlook

Our AI price prediction model suggests that Scilex Holding Company stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 260.29%, with price expected at $0.49 by November 24, 2023, within a range of $0.40 to $0.58

Key Takeaways

Scilex Holding Company (NASDAQ:SCLXW) shares are flat 2.43% year-to-date Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Scilex Holding Company trading at a premium to the broader market with a P/E of -0.21.

Frequently Asked Questions

What is the current Scilex Holding Company (SCLXW) stock price?

Scilex Holding Company (NASDAQ: SCLXW) stock price is $0.14 in the last trading session. During the trading session, SCLXW stock reached the peak price of $0.14 while $0.12 was the lowest point it dropped to. The percentage change in SCLXW stock occurred in the recent session was -0.29% while the dollar amount for the price change in SCLXW stock was - $0.00.

SCLXW's industry and sector of operation?

The NASDAQ listed SCLXW is part of Drug Manufacturers - General industry that operates in the broader Healthcare sector. Scilex Holding Company designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of SCLXW?

Mr. Suketu D. Desai Ph.D.
Chief Technical Officer
Mr. Steven F. Lincoln J.D.
Interim Gen. Counsel & Chief Compliance Officer
Mr. Jaisim Shah
Pres, Chief Executive Officer & Director
Dr. Dmitri V. Lissin M.D.
Senior Vice President & Chief Medical Officer
Mr. Suresh K. Khemani
Senior Vice President & Chief Commercial Officer
Dr. Henry H. Ji Ph.D.
Executive Chairman
Ms. Elizabeth Adkins Czerepak M.B.A.
Executive Vice President, Chief Financial Officer, Chief Bus. Officer & Sec.

How SCLXW did perform over past 52-week?

SCLXW's closing price is 38.22% higher than its 52-week low of $0.10 where as its distance from 52-week high of $0.17 is -17.88%.

How many employees does SCLXW have?

Number of SCLXW employees currently stands at 115.

Link for SCLXW official website?

Official Website of SCLXW is: https://www.scilexholding.com

How do I contact SCLXW?

SCLXW could be contacted at phone 650 516 4310 and can also be accessed through its website. SCLXW operates from 960 San Antonio Road, Palo Alto, CA 94303, United States.

How many shares of SCLXW are traded daily?

SCLXW stock volume for the day was 5 shares. The average number of SCLXW shares traded daily for last 3 months was 18.66K.

What is the market cap of SCLXW currently?

The market value of SCLXW currently stands at $1.19M with its latest stock price at $0.14 and 8.54M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	115
Beta	1.37
Sales or Revenue	$46.74M
5Y Sales Change%	1.407%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Drug Manufacturers - General

SCLXW Company Profile and Key Details

Scilex

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Stock Snapshot

Technical Performance

Earnings & Analyst Outlook

Financial & Profitability Overview

Quarterly Financial Highlights

Company Overview

Dividend & Fair Value

Price Forecast & Outlook

Key Takeaways

Valuation Metrics